Dole, Employees Give to Restore and Rebuild Devastated Central America
1.6.2021 17:15:00 EEST | Business Wire | Press release
On November 3, 2020 Hurricane Eta made landfall in Central America as a powerful Category 4 storm. Just two weeks later Hurricane Iota, a Category 5 storm followed nearly the same path through the region, unleashing heavy rains, winds, massive flooding and severe landslides, causing widespread destruction.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210601005255/en/
Replanting bananas in Honduras. Restoring fields and livelihoods destroyed by Hurricanes Eta and Iota in November 2020. (Photo: Business Wire)
Communities and towns in Honduras and Guatemala - many that support Dole farms and workers – were leveled in the wake. Though Dole was able to successfully evacuate its workers and families prior to the hurricanes’ arrivals, many others were not as fortunate and lost their lives or livelihoods, their possessions and their crops. In the aftermath, water was needed to drink, homes were in need of repair, and clothes, supplies and appliances in need of replacement.
As an organization closely connected to these communities through the banana industry, Dole swiftly moved to lend aid and resources. But not just the company as an entity stepped in, many Dole employees, partners, and public supporters —no matter how far physically from these communities — also contributed their own time and their own funds to help.
In these six months since the hurricanes’ devastation much has been accomplished.
- Dole employees, the company and the public together raised, collected and donated a quarter of a million dollars to purchase food baskets of essential food items -- red beans, rice, corn flour, vegetable oil and powdered milk, capable of feeding a family of five for a month. These food baskets were distributed to 10,000 families in-need in communities surrounding our operations and through relief organizations CEPUDO and the Cortés Chamber of Commerce with established distribution networks in other areas.
- The Red Cross of Honduras received donations of dozens of boxes of clothing and footwear contributed by Dole employees in North America and Dole’s Standard Fruit De Honduras. In addition to 500,000 Lempiras ($20,000US) to help those in need and provide support.
- Dole provided use of company machinery and heavy equipment to repair public services, bridges, roads, and highways.
- Dole allocated space on southbound vessels to humanitarian organizations importing and distributing disaster relief goods and equipment.
- With many banana production areas completely destroyed, Dole, as a major employer of choice in the region, has expedited efforts to restore banana plantations to full production. Farm land preparation takes time and is completely tailored to the conditions of each agricultural area, yet returning jobs and paychecks to the areas quickly is critical.
“I cannot sufficiently convey the heartbreaking destruction these communities endured,” said Nelson Montoya President of Dole Fresh Fruit North America. “However, this catastrophe did not defeat them. The compassion, resiliency and camaraderie of all those on our team in Honduras and Guatemala has been inspiring to me. We will continue to invest in getting everyone back on their feet.”
The investment reached a significant milestone in the rehabilitation process in Honduras, with the first planting of new banana fields at Mendez Farm, Barimasa Zone on May 4, followed closely with planting at Copote Farm in the Isletas Zone and most recently the Palo Verde farm in the Coyoles Zone.
As the company works to restore production volumes derived from these devastated areas in Honduras and Guatemala, Dole expects customers will begin receiving Dole premium fruit from these regions in January 2022.
About Dole Food Company
Dole Food Company, Inc., is one of the world’s largest producers and marketers of high-quality fresh fruit and fresh vegetables. Dole is an industry leader in many of the products it sells, as well as in nutrition education. For more information, please visit www.dole.com .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210601005255/en/
Contact information
William Goldfield
818-874-4647
william.goldfield@dole.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
